Study Shows Quanterix's Single Molecule Array Assay Measures PSA at Previously Undetectable Levels
June 11, 2010
Study Shows Quanterix's Single Molecule Array Assay Measures PSA at Previously Undetectable Levels
The results offer the prospect for improved detection and measurement of low-concentration proteins – a development that has potentially broad applications in protein biomarker research, diagnostics, and drug development, David Duffy, senior director of platform research at Quanterix, told ProteoMonitor.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Shifting Focus From Dx Development, Quanterix Aims to Launch Commercial SiMoA Instrument in 2013
February 25, 2011 / ProteoMonitor - Quanterix Raises $2.5M in Financing Round Targeting $5M
October 15, 2010 / ProteoMonitor - Quanterix and Sony DADC Ink Co-Development Deal for SiMoA Consumables
July 22, 2011 / ProteoMonitor - Quanterix, Gothenberg Researchers Show Potential Link Between Heart Attacks and Alzheimer's Marker
April 15, 2011 / ProteoMonitor - Proteomics Firms Net More than $8.75M in IRS Funds; Bulk of Awards Aimed at Diagnostics Work
November 5, 2010 / ProteoMonitor